Related Experiment Video
Updated: Apr 24, 2026
09:00
Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment
Published on: June 24, 2020
3.0K
IL-6 in inflammation, immunity, and disease
Toshio Tanaka1, Masashi Narazaki2, Tadamitsu Kishimoto3
1Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan Department of Immunopathology, World Premier International Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
Cold Spring Harbor Perspectives in Biology
|September 6, 2014
Summary
Interleukin 6 (IL-6) is vital for host defense but its dysregulated production drives chronic inflammation. Tocilizumab targets the IL-6 receptor, offering effective treatment for autoimmune diseases like rheumatoid arthritis.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Interleukin 6 (IL-6) is a cytokine crucial for immune responses, acute phase reactions, and hematopoiesis.
- While tightly regulated, aberrant IL-6 synthesis is implicated in chronic inflammation and autoimmune diseases.
- Dysregulated IL-6 signaling contributes to the pathogenesis of various immune-mediated conditions.
Purpose of the Study:
- To review the role of Interleukin 6 (IL-6) in host defense and disease pathogenesis.
- To highlight the therapeutic potential of targeting IL-6 signaling pathways.
- To emphasize the need for understanding IL-6 synthesis mechanisms for novel therapeutic development.
Main Methods:
- Literature review of IL-6 biology and therapeutic interventions.
- Analysis of clinical trial data for IL-6 targeted therapies.
- Synthesis of current understanding on IL-6 regulation and its pathological implications.
Main Results:
- Tocilizumab, an anti-IL-6 receptor antibody, has demonstrated significant efficacy in treating rheumatoid arthritis and juvenile idiopathic arthritis.
- IL-6 plays a dual role in host defense and disease, with its dysregulation leading to pathology.
- Clinical success of tocilizumab validates IL-6 receptor blockade as a therapeutic strategy.
Conclusions:
- Targeting the IL-6 receptor with tocilizumab is an effective treatment for specific autoimmune and inflammatory conditions.
- Further elucidation of IL-6 continual synthesis mechanisms is essential for developing more targeted therapies.
- IL-6 pathway modulation holds promise for managing other intractable immune-mediated diseases.
Related Concept Videos
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
01:28Inflammatory Response
12.4K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
12.4K
01:20The JAK-STAT Signaling Pathway
10.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.1K
01:25Inflammatory Bowel Disease III: Crohn's Disease
22
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
22
01:12Chronic Inflammation: Introduction
14
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
14
01:28Inflammation: Introduction
46
Inflammation is a fundamental, protective biological response of vascularized tissues to cellular injury, infection, or harmful stimuli. Its primary function is to eliminate the initial cause of injury, clear necrotic cells and damaged tissue, and initiate the necessary repair processes.Cardinal SignsAcute inflammation presents with classic signs. Redness results from vasodilation and increased blood flow. Heat is due to increased metabolism and circulation. Swelling results from the...
46